OTCMKTS:SVON - Sevion Therapeutics Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.30 -0.05 (-14.29 %)
(As of 05/20/2018 04:00 PM ET)
Previous Close$0.30
Today's Range$0.29 - $0.3650
52-Week Range$0.13 - $0.44
Volume533,681 shs
Average Volume97,866 shs
Market Capitalization$367.62 million
P/E RatioN/A
Dividend YieldN/A
Beta1.46

About Sevion Therapeutics (OTCMKTS:SVON)

Sevion Therapeutics logoEloxx Pharmaceuticals, Inc., formerly Sevion Therapeutics, Inc., is a development-stage biotech company. The Company is engaged in building and developing a portfolio of therapeutics, from both internal discovery and acquisition, for the treatment of cancer and immunological diseases. The Company is engaged in the development and licensing of technology to discover and engineer monoclonal antibodies. The Company's product candidates are derived from multiple technology platforms, such as cell-based arrayed antibody discovery, ultralong antibody scaffolds and Chimerasome nanocages. The Company has various antibodies in its preclinical pipeline. The Company's antibody therapeutic candidates target the potassium channel, voltage dependent (Kv1.3) ion channel, which is essential in the pathogenesis of several autoimmune and inflammatory disorders. Other antibodies in its pipeline target cell surface molecules involved in cancer progression.

Receive SVON News and Ratings via Email

Sign-up to receive the latest news and ratings for SVON and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry N/A
Sub-IndustryN/A
SectorN/A
SymbolOTCMKTS:SVON
CUSIPN/A
Phone+1-858-9090749

Debt

Debt-to-Equity RatioN/A
Current Ratio0.96
Quick Ratio0.96

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual Sales$80,000.00
Price / Sales209.85
Cash FlowN/A
Price / CashN/A
Book Value$0.03 per share
Price / Book10.00

Profitability

EPS (Most Recent Fiscal Year)N/A
Net Income$-5,790,000.00
Net MarginsN/A
Return on Equity-264.80%
Return on Assets-81.73%

Miscellaneous

Employees4
Outstanding Shares55,960,000

Sevion Therapeutics (OTCMKTS:SVON) Frequently Asked Questions

What is Sevion Therapeutics' stock symbol?

Sevion Therapeutics trades on the OTCMKTS under the ticker symbol "SVON."

How were Sevion Therapeutics' earnings last quarter?

Sevion Therapeutics Inc (OTCMKTS:SVON) issued its quarterly earnings results on Monday, May, 22nd. The company reported ($0.09) earnings per share for the quarter. View Sevion Therapeutics' Earnings History.

Who are Sevion Therapeutics' key executives?

Sevion Therapeutics' management team includes the folowing people:
  • Robert E. Ward, Chairman of the Board, Chief Executive Officer (Age 60)
  • Gregory L. Weaver, Chief Financial Officer, Principal Accounting Officer (Age 61)
  • Pedro Huertas, Chief Medical Officer
  • Zafrira Avnur, Director
  • Tomer Kariv, Director
  • Martijn Kleijwegt, Director
  • Ran Nussbaum, Director (Age 44)
  • Steven Rubin, Director (Age 57)

Has Sevion Therapeutics been receiving favorable news coverage?

News headlines about SVON stock have been trending somewhat positive on Sunday, Accern Sentiment reports. The research group identifies positive and negative news coverage by reviewing more than 20 million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Sevion Therapeutics earned a media sentiment score of 0.18 on Accern's scale. They also assigned media coverage about the company an impact score of 44.79 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company's share price in the near future.

How do I buy shares of Sevion Therapeutics?

Shares of SVON can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Sevion Therapeutics' stock price today?

One share of SVON stock can currently be purchased for approximately $0.30.

How big of a company is Sevion Therapeutics?

Sevion Therapeutics has a market capitalization of $367.62 million and generates $80,000.00 in revenue each year. Sevion Therapeutics employs 4 workers across the globe.

How can I contact Sevion Therapeutics?

Sevion Therapeutics' mailing address is 950 Winter St, WALTHAM, MA 02451-1424, United States. The company can be reached via phone at +1-858-9090749 or via email at [email protected]


MarketBeat Community Rating for Sevion Therapeutics (SVON)

Community Ranking:  2.5 out of 5 (star star half star)
Outperform Votes:  34 (Vote Outperform)
Underperform Votes:  35 (Vote Underperform)
Total Votes:  69
MarketBeat's community ratings are surveys of what our community members think about Sevion Therapeutics and other stocks. Vote "Outperform" if you believe SVON will outperform the S&P 500 over the long term. Vote "Underperform" if you believe SVON will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Sevion Therapeutics (OTCMKTS:SVON) Analyst Ratings History

DateBrokerageActionRatingPrice TargetDetails
(Data available from 5/20/2016 forward)

Earnings

Sevion Therapeutics (OTCMKTS:SVON) Earnings History and Estimates Chart

Earnings by Quarter for Sevion Therapeutics (OTCMKTS:SVON)

Sevion Therapeutics (OTCMKTS SVON) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/22/2017Q3 2017($0.09)ViewN/AView Earnings Details
11/17/2014Q1 15($0.38)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Sevion Therapeutics (OTCMKTS:SVON) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Sevion Therapeutics (OTCMKTS SVON) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 7.70%
Insider Trading History for Sevion Therapeutics (OTCMKTS:SVON)

Sevion Therapeutics (OTCMKTS SVON) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/29/2015Phillip Md Et Al FrostDirectorBuy35,000$0.61$21,350.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Sevion Therapeutics (OTCMKTS SVON) News Headlines

Source:
DateHeadline
Head-To-Head Comparison: Sevion Therapeutics (SVON) vs. XOMA (XOMA)Head-To-Head Comparison: Sevion Therapeutics (SVON) vs. XOMA (XOMA)
www.americanbankingnews.com - February 25 at 9:18 PM
Comparing Sevion Therapeutics (SVON) & VBI Vaccines (VBIV)Comparing Sevion Therapeutics (SVON) & VBI Vaccines (VBIV)
www.americanbankingnews.com - February 16 at 5:18 AM
Head-To-Head Analysis: SIGA Technologies (SIGA) vs. Sevion Therapeutics (SVON)Head-To-Head Analysis: SIGA Technologies (SIGA) vs. Sevion Therapeutics (SVON)
www.americanbankingnews.com - January 25 at 7:14 PM
Sevion Therapeutics (SVON) vs. Aevi Genomic Medicine (GNMX) Head-To-Head ContrastSevion Therapeutics (SVON) vs. Aevi Genomic Medicine (GNMX) Head-To-Head Contrast
www.americanbankingnews.com - January 11 at 1:10 AM
Critical Comparison: Mirati Therapeutics (MRTX) & Sevion Therapeutics (SVON)Critical Comparison: Mirati Therapeutics (MRTX) & Sevion Therapeutics (SVON)
www.americanbankingnews.com - January 4 at 1:30 AM
Financial Comparison: Sevion Therapeutics (SVON) and Tetralogic Pharmaceuticals (TLOG)Financial Comparison: Sevion Therapeutics (SVON) and Tetralogic Pharmaceuticals (TLOG)
www.americanbankingnews.com - December 30 at 5:20 AM
Eloxx Pharmaceuticals Completes Acquisition Transaction with Sevion TherapeuticsEloxx Pharmaceuticals Completes Acquisition Transaction with Sevion Therapeutics
finance.yahoo.com - December 20 at 9:00 AM
Sevion Therapeutics Announces 1-for-20 Reverse Stock SplitSevion Therapeutics Announces 1-for-20 Reverse Stock Split
finance.yahoo.com - December 19 at 5:46 PM
Sevion Therapeutics (SVON) Downgraded to Sell at ValuEngineSevion Therapeutics (SVON) Downgraded to Sell at ValuEngine
www.americanbankingnews.com - December 2 at 4:04 PM
Financial Comparison: Mateon Therapeutics (MATN) vs. Sevion Therapeutics (SVON)Financial Comparison: Mateon Therapeutics (MATN) vs. Sevion Therapeutics (SVON)
www.americanbankingnews.com - December 2 at 3:28 AM
Eloxx Pharmaceuticals Announces First Patient Dosed in Phase 1b Clinical TrialEloxx Pharmaceuticals Announces First Patient Dosed in Phase 1b Clinical Trial
finance.yahoo.com - November 27 at 4:06 PM
Reviewing Senesco Technologies (SVON) & Mateon Therapeutics (MATN)Reviewing Senesco Technologies (SVON) & Mateon Therapeutics (MATN)
www.americanbankingnews.com - November 20 at 3:20 PM
Eloxx Pharmaceuticals Announces Expansion of Intellectual Property Estate for ELX-02 with Newly Granted Patent in EuropeEloxx Pharmaceuticals Announces Expansion of Intellectual Property Estate for ELX-02 with Newly Granted Patent in Europe
finance.yahoo.com - October 17 at 7:45 AM
Senesco Technologies (SVON) and The Competition Critical AnalysisSenesco Technologies (SVON) and The Competition Critical Analysis
www.americanbankingnews.com - October 14 at 6:20 PM
Critical Review: Senesco Technologies (SVON) & The CompetitionCritical Review: Senesco Technologies (SVON) & The Competition
www.americanbankingnews.com - September 28 at 8:28 AM
Reviewing Senesco Technologies (SVON) and The CompetitionReviewing Senesco Technologies (SVON) and The Competition
www.americanbankingnews.com - September 23 at 2:32 PM
Analyzing Senesco Technologies (SVON) & Its RivalsAnalyzing Senesco Technologies (SVON) & Its Rivals
www.americanbankingnews.com - September 22 at 12:18 PM
Senesco Technologies (SVON) vs. The Competition Head-To-Head ComparisonSenesco Technologies (SVON) vs. The Competition Head-To-Head Comparison
www.americanbankingnews.com - September 21 at 12:22 AM
Eloxx Pharmaceuticals Expands Management Team to Support Rapid Development of Lead Drug Candidate ELX-02 for the Treatment of Rare Genetic DiseasesEloxx Pharmaceuticals Expands Management Team to Support Rapid Development of Lead Drug Candidate ELX-02 for the Treatment of Rare Genetic Diseases
finance.yahoo.com - September 8 at 8:56 AM
Comparing Senesco Technologies (SVON) & Windtree Therapeutics (WINT)Comparing Senesco Technologies (SVON) & Windtree Therapeutics (WINT)
www.americanbankingnews.com - September 5 at 2:15 PM
SEVION THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of EquitySEVION THERAPEUTICS, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Unregistered Sale of Equity
biz.yahoo.com - February 22 at 8:18 PM

SEC Filings

Sevion Therapeutics (OTCMKTS:SVON) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Sevion Therapeutics (OTCMKTS:SVON) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Sevion Therapeutics (OTCMKTS SVON) Stock Chart for Sunday, May, 20, 2018

Loading chart…

This page was last updated on 5/20/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.